Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics
Published Time:
2024-07-02 17:28
Source:
On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.
VC004, a second-generation NTRK inhibitor independently developed by Jiangsu Vcare, has demonstrated excellent in vitro and in vivo activity, favorable pharmacokinetic properties, good tolerability, and high response rates in early clinical studies. With no second-generation NTRK inhibitors currently approved in China, VC004 is poised to fill this critical gap.
Jiangsu Vcare: Specializes in the development of innovative drugs and advanced therapies, with deep expertise in R&D and market expansion across oncology, cardiovascular and cerebrovascular diseases, autoimmune disorders, and other therapeutic areas. The company has developed multiple clinical-stage Class I innovative drugs and clinical solutions.
Geneseeq: A leading Chinese precision oncology testing company, Geneseeq possesses advanced high-throughput gene sequencing technologies and extensive experience in diagnostic kit development and regulatory approval. It is the only domestic enterprise with two NGS-based innovative medical device reagent products.
The partnership will leverage the complementary strengths of both parties to accelerate the development and commercialization of VC004’s companion diagnostics, promote the clinical application of NTRK1/2/3 gene fusion detection, and deliver transformative benefits to cancer patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: “VC004, our self-developed next-generation NTRK inhibitor, is currently in a critical Phase II clinical trial in China. We are honored to partner with our ‘neighbor’ Geneseeq at this pivotal stage. Geneseeq has achieved remarkable success in translating gene sequencing technologies into clinical applications. This collaboration will integrate VC004’s research advancements with Geneseeq’s diagnostic expertise, profoundly addressing unmet clinical needs. We look forward to contributing to medical progress and human health through this partnership.”
Dr. Wang Xiaonan, Co-founder and Chief Technology Officer of Geneseeq, remarked: “As fellow enterprises in Nanjing’s Jiangbei New District, Geneseeq and Jiangsu Vcare have collaborated for years. Both companies prioritize innovation, driven by clinical demand, to achieve high-quality development. I am confident that this strategic alliance will accelerate the efficiency of innovative drug R&D and clinical application, ultimately providing patients with more therapeutic options and greater survival benefits.”
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn